Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1966 1
1975 5
1976 2
1977 1
1979 1
1980 3
1981 1
1982 3
1984 4
1985 1
1986 3
1987 2
1988 1
1989 2
1990 3
1991 2
1992 1
1993 3
1994 1
1995 8
1996 3
1997 6
1998 7
1999 6
2000 3
2001 5
2002 11
2003 7
2004 3
2005 5
2006 5
2007 16
2008 9
2009 18
2010 16
2011 16
2012 15
2013 18
2014 8
2015 27
2016 29
2017 26
2018 28
2019 22
2020 39
2021 46
2022 53
2023 35
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Huang DQ, et al. Among authors: ishigami m. Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Hepatology. 2023. PMID: 37184202
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Taylor RS, et al. Among authors: ishigami m. Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4. Gastroenterology. 2020. PMID: 32027911 Free article.
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwamoto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, Toyoda H, Kanto T. Yamauchi R, et al. Among authors: ishigami m. J Gastroenterol. 2023 Jun;58(6):565-574. doi: 10.1007/s00535-023-01985-w. Epub 2023 Mar 30. J Gastroenterol. 2023. PMID: 36991155
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH. Wong YJ, et al. Among authors: ishigami m. Hepatol Int. 2023 Oct;17(5):1150-1161. doi: 10.1007/s12072-023-10547-4. Epub 2023 Jun 5. Hepatol Int. 2023. PMID: 37273170
Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, Kim HL, Arai T, Atsukawa M, Kawanaka M, Toyoda H, Ishigami M, Yu ML, Jun DW, Nguyen MH. Park H, et al. Among authors: ishigami m. JAMA Netw Open. 2023 Aug 1;6(8):e2329568. doi: 10.1001/jamanetworkopen.2023.29568. JAMA Netw Open. 2023. PMID: 37589973 Free PMC article.
The effects of ustekinumab on small intestinal lesions and stenotic lesions.
Wada H, Murate K, Nakamura M, Furukawa K, Kakushima N, Yamamura T, Maeda K, Sawada T, Ishikawa E, Ishikawa T, Ohno E, Honda T, Kawashima H, Nakayama G, Hattori N, Umeda S, Ishigami M. Wada H, et al. Among authors: ishigami m. Nagoya J Med Sci. 2022 Nov;84(4):825-838. doi: 10.18999/nagjms.84.4.825. Nagoya J Med Sci. 2022. PMID: 36544611 Free PMC article.
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Won Jun D, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH. Huang DQ, et al. Among authors: ishigami m. J Clin Oncol. 2024 Mar 1;42(7):790-799. doi: 10.1200/JCO.23.00757. Epub 2024 Jan 4. J Clin Oncol. 2024. PMID: 38175991
476 results